Y-mAbs Therapeutics Inc
YMAB4.375USD
-0.155-3.42%
交易中 （美东）报价延迟15分钟
197.97M总市值
亏损市盈率 TTM
关于 Y-mAbs Therapeutics Inc 公司
Y-mAbs Therapeutics, Inc. 是一家商业阶段的生物制药公司，专注于开发和商业化放射免疫疗法和基于抗体的治疗癌症产品。其技术包括其研究性自组装拆卸 (SADA) 预定位放射免疫疗法平台和使用 Y-BiClone 平台生成的双特异性抗体。其先进的产品线包括抗 GD2 疗法 DANYELZA (naxitamab-gqgk)，这是美国食品药品管理局 (FDA) 批准的一种疗法，用于治疗对先前疗法有部分反应、轻微反应或病情稳定的骨或骨髓中复发或难治性神经母细胞瘤患者。DANYELZA 是一种人源化免疫球蛋白 G、亚型 1k (IgG1k) 单克隆抗体 (mAb)，靶向神经节苷脂 GD2，该物质在各种神经外胚层衍生的肿瘤和肉瘤中表达。 Omburtamab 的靶点是 B7-H3，这是一种在多种癌症类型的肿瘤细胞中表达的免疫检查点分子。
公司简介
公司代码YMAB
公司名称Y-mAbs Therapeutics Inc
上市日期Sep 21, 2018
CEOMr. Michael Rossi
员工数量107
证券类型Ordinary Share
年结日Sep 21
公司地址202 Carnegie Center
城市PRINCETON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编08540
电话16468858505
网址https://www.ymabs.com/
公司代码YMAB
上市日期Sep 21, 2018
CEOMr. Michael Rossi
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas Gad
Mr. Thomas Gad
Vice Chairman of the Board, Founder, Chief Business Officer
Vice Chairman of the Board, Founder, Chief Business Officer
373.17K
+38.12%
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.19K
+89.23%
Mr. Johan Wedell-Wedellsborg
Mr. Johan Wedell-Wedellsborg
Independent Director
Independent Director
27.41K
+1076.39%
Mr. David N. Gill, CPA
Mr. David N. Gill, CPA
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Ashutosh Tyagi, M.D.
Dr. Ashutosh Tyagi, M.D.
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Mary Tagliaferri, M.D.
Dr. Mary Tagliaferri, M.D.
Independent Director
Independent Director
1.55K
--
Mr. Peter P. Pfreundschuh, CPA
Mr. Peter P. Pfreundschuh, CPA
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Mr. Douglas J Gentilcore
Mr. Douglas J Gentilcore
Senior Vice President, Danyelza Business Unit Head
Senior Vice President, Danyelza Business Unit Head
--
--
Ms. Laura Jean Hamill
Ms. Laura Jean Hamill
Independent Director
Independent Director
--
--
Mr. Joris Wiel Jan Wilms
Mr. Joris Wiel Jan Wilms
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Thomas Gad
Mr. Thomas Gad
Vice Chairman of the Board, Founder, Chief Business Officer
Vice Chairman of the Board, Founder, Chief Business Officer
373.17K
+38.12%
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.19K
+89.23%
Mr. Johan Wedell-Wedellsborg
Mr. Johan Wedell-Wedellsborg
Independent Director
Independent Director
27.41K
+1076.39%
Mr. David N. Gill, CPA
Mr. David N. Gill, CPA
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Ashutosh Tyagi, M.D.
Dr. Ashutosh Tyagi, M.D.
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Mary Tagliaferri, M.D.
Dr. Mary Tagliaferri, M.D.
Independent Director
Independent Director
1.55K
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2024Q2
暂无数据
地区USD
名称
营收
占比
United States
65.98M
77.46%
Eastern Asia
7.46M
8.75%
Latin America
4.72M
5.54%
Western Asia
4.05M
4.76%
Western Europe
2.09M
2.45%
Other region
890.00K
1.04%
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
WG Biotech ApS
10.07%
Paradigm BioCapital Advisors LP
9.35%
HBM Partners AG
7.28%
Acorn Capital Advisors, LLC
6.10%
BlackRock Institutional Trust Company, N.A.
5.65%
Other
61.55%
持股股东
持股股东
占比
WG Biotech ApS
10.07%
Paradigm BioCapital Advisors LP
9.35%
HBM Partners AG
7.28%
Acorn Capital Advisors, LLC
6.10%
BlackRock Institutional Trust Company, N.A.
5.65%
Other
61.55%
股东类型
持股股东
占比
Investment Advisor
26.79%
Hedge Fund
20.03%
Investment Advisor/Hedge Fund
15.62%
Corporation
10.07%
Venture Capital
5.05%
Research Firm
2.73%
Individual Investor
2.18%
Bank and Trust
0.21%
Pension Fund
0.16%
Other
17.17%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
264
37.72M
83.28%
-923.46K
2025Q1
277
38.42M
85.49%
-1.59M
2024Q4
273
40.45M
90.45%
-6.61K
2024Q3
291
40.17M
90.02%
+2.08M
2024Q2
285
38.93M
87.51%
+1.55M
2024Q1
287
37.98M
86.27%
+2.28M
2023Q4
288
35.14M
80.00%
-1.12M
2023Q3
292
32.75M
75.02%
-3.59M
2023Q2
292
32.24M
73.87%
-4.59M
2023Q1
293
31.07M
71.14%
-6.37M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
WG Biotech ApS
4.56M
10.07%
--
--
May 23, 2025
Paradigm BioCapital Advisors LP
4.24M
9.35%
--
--
Mar 31, 2025
HBM Partners AG
3.30M
7.28%
--
--
May 23, 2025
Acorn Capital Advisors, LLC
2.76M
6.1%
--
--
May 23, 2025
BlackRock Institutional Trust Company, N.A.
2.56M
5.65%
-129.60K
-4.82%
Mar 31, 2025
Caligan Partners, LP
2.34M
5.17%
+574.63K
+32.50%
Mar 31, 2025
Sofinnova Investments, Inc
2.19M
4.84%
--
--
May 23, 2025
The Vanguard Group, Inc.
1.95M
4.3%
-46.73K
-2.34%
Mar 31, 2025
Polar Capital LLP
1.83M
4.04%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
849.50K
1.88%
+27.19K
+3.31%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
0.14%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
占比0.14%
iShares Micro-Cap ETF
占比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
